11/19
08:20 am
anix
Anixa Biosciences, Inc. (NASDAQ: ANIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Low
Report
Anixa Biosciences, Inc. (NASDAQ: ANIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
11/18
08:20 am
anix
Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial
Low
Report
Anixa Biosciences Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial
11/14
05:18 pm
anix
Breast cancer vaccine update from Cleveland Clinic: ‘A new era' [FOX News]
Medium
Report
Breast cancer vaccine update from Cleveland Clinic: ‘A new era' [FOX News]
11/8
01:23 pm
anix
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting [Yahoo! Finance]
Low
Report
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting [Yahoo! Finance]
11/8
01:17 pm
anix
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Medium
Report
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
11/6
08:30 am
anix
Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Low
Report
Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
10/31
08:15 am
anix
Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024
Medium
Report
Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024
10/28
08:30 am
anix
Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
High
Report
Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
10/16
05:51 am
anix
Anixa Biosciences administers second CAR-T dose in ovarian cancer trial [Yahoo! Finance]
Medium
Report
Anixa Biosciences administers second CAR-T dose in ovarian cancer trial [Yahoo! Finance]
10/15
09:00 am
anix
Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial
Medium
Report
Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial
10/7
08:30 am
anix
Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development
Low
Report
Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development
9/30
08:30 am
anix
Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial
Low
Report
Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial
9/25
05:52 am
anix
Anixa announces plans to launch Phase II breast cancer vaccine trial [Yahoo! Finance]
Medium
Report
Anixa announces plans to launch Phase II breast cancer vaccine trial [Yahoo! Finance]
9/24
08:30 am
anix
Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine
Medium
Report
Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine
9/18
08:30 am
anix
Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer Research Alliance's International Gynecologic Cancer Conference
Medium
Report
Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer Research Alliance's International Gynecologic Cancer Conference
9/17
08:02 am
anix
Anixa Biosciences, Inc. (NASDAQ: ANIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
Medium
Report
Anixa Biosciences, Inc. (NASDAQ: ANIX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
9/5
11:02 am
anix
Cancer Vaccines Industry Research Report 2024: Market Poised for Exponential Growth with a Projected Value of $6.7 Billion by 2032 [Yahoo! Finance]
Medium
Report
Cancer Vaccines Industry Research Report 2024: Market Poised for Exponential Growth with a Projected Value of $6.7 Billion by 2032 [Yahoo! Finance]
9/3
08:30 am
anix
Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research Symposium
Low
Report
Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research Symposium
8/26
08:52 am
anix
Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference [Yahoo! Finance]
Medium
Report
Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference [Yahoo! Finance]
8/26
08:30 am
anix
Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Medium
Report
Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference